Lack of OATP1B1 and OAT3 inhibition potential for ritlecitinib was further supported by endogenous biomarker data of CP-I and PDA, as no changes of their plasma exposure were observed. The gene discussed is SLC22A8; the disease is Patent ductus arteriosus.